179 related articles for article (PubMed ID: 20065267)
1. Use of multiattribute utility theory for formulary management in a health system.
Chung S; Kim S; Kim J; Sohn K
Am J Health Syst Pharm; 2010 Jan; 67(2):128-35. PubMed ID: 20065267
[TBL] [Abstract][Full Text] [Related]
2. Multiattribute evaluation in formulary decision making as applied to calcium-channel blockers.
Schumacher GE
Am J Hosp Pharm; 1991 Feb; 48(2):301-8. PubMed ID: 2003506
[TBL] [Abstract][Full Text] [Related]
3. Amlodipine besylate/olmesartan medoximil fixed combination for the treatment of hypertension.
Chrysant SG
Expert Rev Cardiovasc Ther; 2009 Aug; 7(8):887-95. PubMed ID: 19673666
[TBL] [Abstract][Full Text] [Related]
4. Exforge HCT.
Med Lett Drugs Ther; 2009 Jun; 51(1314):47. PubMed ID: 19528888
[No Abstract] [Full Text] [Related]
5. HYT-hypertension in Turkey: a cross-sectional survey on blood pressure control with calcium channel blockers alone or combined with other antihypertensive drugs.
Seravalle G; Koylan N; Nalbantgil I; Caglar N; Quarti-Trevano F; Makel W; Grassi G; Fici F
High Blood Press Cardiovasc Prev; 2015 Jun; 22(2):165-72. PubMed ID: 25900022
[TBL] [Abstract][Full Text] [Related]
6. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
[TBL] [Abstract][Full Text] [Related]
7. A comparison of two multiple-characteristic decision-making models for the comparison of antihypertensive drug classes: Simple Additive Weighting (SAW) and Technique for Order Preference by Similarity to an Ideal Solution (TOPSIS).
Van Wijk BL; Klungel OH; Heerdink ER; de Boer A
Am J Cardiovasc Drugs; 2006; 6(4):251-8. PubMed ID: 16913826
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the efficacy and safety of fixed-dose amlodipine/losartan and losartan in hypertensive patients inadequately controlled with losartan: a randomized, double-blind, multicenter study.
Hong BK; Park CG; Kim KS; Yoon MH; Yoon HJ; Yoon JH; Yang JY; Choi YJ; Cho SY
Am J Cardiovasc Drugs; 2012 Jun; 12(3):189-95. PubMed ID: 22462558
[TBL] [Abstract][Full Text] [Related]
9. A meta-analysis of the effect of angiotensin receptor blockers and calcium channel blockers on blood pressure, glycemia and the HOMA-IR index in non-diabetic patients.
Yang Y; Wei RB; Xing Y; Tang L; Zheng XY; Wang ZC; Gao YW; Li MX; Chen XM
Metabolism; 2013 Dec; 62(12):1858-66. PubMed ID: 24050270
[TBL] [Abstract][Full Text] [Related]
10. Strategies for success in creating an effective multihospital health-system pharmacy and therapeutics committee.
Leonard MC; Thyagarajan R; Wilson AJ; Sekeres MA
Am J Health Syst Pharm; 2018 Apr; 75(7):451-455. PubMed ID: 29572313
[TBL] [Abstract][Full Text] [Related]
11. Schizophrenia: multi-attribute utility theory approach to selection of atypical antipsychotics.
Bettinger TL; Shuler G; Jones DR; Wilson JP
Ann Pharmacother; 2007 Feb; 41(2):201-7. PubMed ID: 17311836
[TBL] [Abstract][Full Text] [Related]
12. Results of a phase III, 8-week, multicenter, prospective, randomized, double-blind, parallel-group clinical trial to assess the effects of amlodipine camsylate versus amlodipine besylate in Korean adults with mild to moderate hypertension.
Kim SH; Kim YD; Lim DS; Yoon MH; Ahn YK; On YK; Lee JW; Kim IJ; Park JB; Kim JJ; Chung WS; Yang JY; Seo HS; Shin EK; Kim HS;
Clin Ther; 2007 Sep; 29(9):1924-36. PubMed ID: 18035192
[TBL] [Abstract][Full Text] [Related]
13. Amlodipine/valsartan single-pill combination: a review of its use in the management of hypertension.
Frampton JE; Scott LJ
Am J Cardiovasc Drugs; 2009; 9(5):309-30. PubMed ID: 19791840
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of angiotensin II type 1 receptor blocker/calcium channel blocker combination therapy for hypertension: focus on a single-pill fixed-dose combination of valsartan and amlodipine.
Miura S; Saku K
J Int Med Res; 2012; 40(1):1-9. PubMed ID: 22429340
[TBL] [Abstract][Full Text] [Related]
15. Contemporary challenges and novel strategies for health-system formulary management.
Heindel GA; McIntyre CM
Am J Health Syst Pharm; 2018 Apr; 75(8):556-560. PubMed ID: 29626005
[No Abstract] [Full Text] [Related]
16. Angiotensin receptor blocker and dihydropyridine calcium channel blocker combinations: an emerging strategy in hypertension therapy.
Oparil S; Weber M
Postgrad Med; 2009 Mar; 121(2):25-39. PubMed ID: 19332960
[TBL] [Abstract][Full Text] [Related]
17. Systolic blood pressure reduction with olmesartan medoxomil versus nitrendipine in elderly patients with isolated systolic hypertension.
Mallion JM; Heagerty A; Laeis P
J Hypertens; 2007 Oct; 25(10):2168-77. PubMed ID: 17885562
[TBL] [Abstract][Full Text] [Related]
18. Triple combination therapy to improve blood pressure control: experience with olmesartan-amlodipine-hydrochlorothiazide therapy.
Tocci G; Paneni F; Passerini J; Volpe M
Expert Opin Pharmacother; 2012 Dec; 13(18):2687-97. PubMed ID: 23170911
[TBL] [Abstract][Full Text] [Related]
19. Cost effectiveness of angiotensin receptor blocker monotherapy in patients with hypertension in the Netherlands: a comparative analysis using clinical trial and drug utilization data.
Boersma C; Voors AA; Visser ST; de Jong-van den Berg LT; Postma MJ
Am J Cardiovasc Drugs; 2010; 10(1):49-54. PubMed ID: 20104934
[TBL] [Abstract][Full Text] [Related]
20. High-dose monotherapy vs low-dose combination therapy of calcium channel blockers and angiotensin receptor blockers in mild to moderate hypertension.
Andreadis EA; Tsourous GI; Marakomichelakis GE; Katsanou PM; Fotia ME; Vassilopoulos CV; Diamantopoulos EJ
J Hum Hypertens; 2005 Jun; 19(6):491-6. PubMed ID: 15759025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
